Our mission is to abolish kidney cancer as a threat to the life and health of patients by supporting patient advocacy and research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can find the cure.
Advocating for the Kidney Cancer Community in D.C.
On March 9-10, members of the kidney cancer community once again gathered in Washington, D.C., to advocate for the kidney cancer community and make the case for research funding. Dozens of KidneyCAN delegates spent two days learning about advocacy and educating policymakers and our elected representatives on issues affecting the kidney cancer community. Our participation in events like these is essential to securing funding for the NIH/NCI and protect funding for the KCRP. As recently as 2016, zero dollars were allocated for kidney cancer research. In 2020, that number is $40 million, and we have the support of our community to thank for that.
There will be additional opportunities to join us in advocacy. You can help today by subscribing to our list for updates and donating to KidneyCAN.
Read more about our efforts on Capitol Hill:
Proceeds from our Rock the Cure events have been used to explore exciting approaches to generate individualized vaccines for kidney cancer patients. The approach will use fresh biopsies from kidney cancer patients to accurately represent their current cancer immune profile. The cells are then cultured and multiplied using a novel cell culture technique and can serve in the future as the basis for a patient specific whole cell or RNA vaccine. The advantage of this approach is that it not only directs the immune system to the specific mutations of the tumor, but also other over expressed common and rare normal proteins and activated retroviruses. Thus, the full repertoire of targets for the immune system will be displayed. While vaccines in the past have been met with moderate benefit at best, they are now poised to synergize with the modern immunotherapy revolution of immune checkpoint inhibitors.
My death sentence was commuted by something called RADVAX — a clinical trial in its second phase being run by Dr. Hans Hammers, a recent Johns Hopkins transplant to UT Southwestern. The trial is being funded by KidneyCAN.
From Our Blog
Funded major projects to date include:
RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.
Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.
Our primary sources of support are donations from the general public and fundraising.
Please enter your information below: